+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Companion Diagnostics Market by Technology (Immunohistochemistry, In Situ Hybridization, Next-Generation Sequencing), Indication (Cancer, Cardiovascular Diseases, Infectious Diseases), End-user - Forecast 2024-2030- Product Image
Global Companion Diagnostics Market by Technology (Immunohistochemistry, In Situ Hybridization, Next-Generation Sequencing), Indication (Cancer, Cardiovascular Diseases, Infectious Diseases), End-user - Forecast 2024-2030- Product Image
Sale

Global Companion Diagnostics Market by Technology (Immunohistochemistry, In Situ Hybridization, Next-Generation Sequencing), Indication (Cancer, Cardiovascular Diseases, Infectious Diseases), End-user - Forecast 2024-2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 5336915
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Companion Diagnostics Market size was estimated at USD 6.64 billion in 2023, USD 7.30 billion in 2024, and is expected to grow at a CAGR of 10.65% to reach USD 13.49 billion by 2030.

Companion diagnostics are specialized tests designed to help healthcare professionals determine whether a particular medical treatment is effective for a patient or to identify the best dosage of medication for that individual. These tests are an integral part of personalized medicine, a medical approach that tailors treatment to the individual characteristics of each patient, such as their lifestyle, genetic makeup, and environment. Companion diagnostics are particularly prevalent in the management of certain cancers, where the effectiveness of the treatment can depend significantly on the genetic alterations present within the tumor.

The push towards personalized medicine, where treatments are optimized for individual patient profiles, significantly drives the demand for companion diagnostics. Moreover, the development of targeted therapies, especially in oncology, necessitates companion diagnostics to identify patients who would most benefit from these treatments. However, the development and implementation of companion diagnostics can be costly, with inadequate reimbursement posing a significant barrier. Furthermore, technologies, including next-generation sequencing and digital PCR, are expanding the capabilities of companion diagnostics, allowing for more comprehensive genetic profiling poses significant opportunities for market growth.

Regional Insights

In the Americas, the demand for companion diagnostics is driven by a robust healthcare infrastructure, heightened awareness about personalized medicine, and significant research and development activities. The U.S. Food and Drug Administration (FDA) has been proactive in approving companion diagnostics, especially for cancer treatments, which underscores the importance of these tools in therapeutic decisions. Investments and initiatives in this region are primarily focused on oncology, cardiovascular diseases, and neurology, reflecting a broader trend toward personalized healthcare solutions.

EU countries exhibit a high demand for companion diagnostics, supported by a strong regulatory framework that promotes innovation while ensuring patient safety. The European Medicines Agency (EMA) plays an vital role in the approval of companion diagnostics across Europe. Consumer needs in the EU are sophisticated, with a high expectation for personalized healthcare services. Middle Eastern countries, such as the United Arab Emirates and Saudi Arabia, are witnessing a growing interest in personalized medicine, which is supported by government initiatives and investments in healthcare infrastructure. Africa, however, faces significant hurdles due to limited healthcare infrastructure and access. In APAC, the market for companion diagnostics is expanding swiftly, fueled by government initiatives aimed at improving healthcare standards and embracing personalized medicine. The government has launched several initiatives to promote precision medicine, including significant investments in genetic research. This focus is gradually translating into increased demand for companion diagnostics, particularly in urban areas with better healthcare facilities.

Market Trends by Segment

  • Technology: Increasing preference of next-generation sequencing in precision medicine
  • End-user: Expansion of pharmaceutical and biopharmaceutical sector driving the significance of companion diagnostics

Industry Insights

  • Market Dynamics
  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
  • FPNV Positioning Matrix
  • Market Share Analysis
  • Strategy Analysis and Recommendations

Recent Developments

Innovative Partnership Between Thermo Fisher Scientific and Bayer Sets New Standard in Precision Cancer Care

Thermo Fisher Scientific has announced a groundbreaking collaboration with Bayer aimed at advancing precision oncology treatments through the development of companion diagnostic assays. Utilizing Thermo Fisher's cutting-edge Ion Torrent Genexus Dx System, this partnership is poised to revolutionize cancer care by enabling the rapid analysis of both liquid and tissue samples within 24 hours, thus facilitating quicker access to targeted therapies for patients.

Strategic Partnership between Agilent and Incyte Elevates Companion Diagnostic Development

Agilent Technologies has announced a strategic collaboration with pharmaceutical company Incyte to advance the development of companion diagnostics. This partnership aims to create diagnostic tests that accurately identify patients who can benefit from targeted treatments, particularly within Incyte’s hematology and oncology portfolio. This collaboration signifies a proactive step towards innovative patient care and a strengthened position in the diagnostics market.

Unlocking New Treatment Horizons: FDA Approves Capivasertib & Fulvestrant Combo for Advanced Breast Cancer, Backed by FoundationOne® CDx Diagnostic Advances

In a significant move towards enhancing treatment options for individuals with advanced hormone receptor-positive, HER2-negative breast cancer, the FDA greenlit the use of capivasertib in conjunction with fulvestrant. This approval targets patients battling locally advanced & metastatic cancer that exhibits specific genetic alterations (PIK3CA, AKT1, or PTEN), post at least one failed endocrine-based regimen, and recurrence within a year post adjuvant therapy.

Key Company Profiles

The report delves into recent significant developments in the Companion Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abnova Corporation, Agendia, Inc., Agilent Technologies, Inc., Almac Group, Amoy Diagnostics Co., Ltd., ARUP Laboratories, Bio-Techne Corporation, Biogenex Laboratories, Inc, bioMérieux SA, Danaher Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, Guardant Health, Inc, ICON PLC, Illumina, Inc., Invivoscribe Technologies, Inc., Myriad Genetics, Inc., NG biotech, QIAGEN N.V., R-Biopharm AG, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc.

This research report offers invaluable insights into various crucial aspects of the Companion Diagnostics Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing significance of companion diagnostics in drug development
5.1.1.2. Increasing demand for personalized medicines and targeted therapy
5.1.1.3. Rise in research and development for innovation in next generation sequencing
5.1.2. Restraints
5.1.2.1. High costs associated with development and implementation of companion diagnostics
5.1.3. Opportunities
5.1.3.1. Ongoing technological advancements in diagnostic techniques
5.1.3.2. Favorable regulatory policies encouraging the development and approval of companion diagnostics
5.1.4. Challenges
5.1.4.1. Reimbursement issues associated with companion diagnostic tests
5.2. Market Segmentation Analysis
5.2.1. Technology: Increasing preference of next-generation sequencing in precision medicine
5.2.2. End-user: Expansion of pharmaceutical and biopharmaceutical sector driving the significance of companion diagnostics
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Companion Diagnostics Market, by Technology
6.1. Introduction
6.2. Immunohistochemistry
6.3. In Situ Hybridization
6.4. Next-Generation Sequencing
6.5. Polymerase Chain Reaction
7. Companion Diagnostics Market, by Indication
7.1. Introduction
7.2. Cancer
7.3. Cardiovascular Diseases
7.4. Infectious Diseases
7.5. Neurological Disorders
8. Companion Diagnostics Market, by End-user
8.1. Introduction
8.2. Pharmaceutical & Biopharmaceutical Companies
8.3. Reference Laboratories
9. Americas Companion Diagnostics Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Companion Diagnostics Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Companion Diagnostics Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Innovative Partnership Between Thermo Fisher Scientific and Bayer Sets New Standard in Precision Cancer Care
12.3.2. Strategic Partnership between Agilent and Incyte Elevates Companion Diagnostic Development
12.3.3. Unlocking New Treatment Horizons: FDA Approves Capivasertib & Fulvestrant Combo for Advanced Breast Cancer, Backed by FoundationOne® CDx Diagnostic Advances
12.4. Strategy Analysis & Recommendation
13. Competitive Portfolio
13.1. Key Company Profiles
13.2. Key Product Portfolio
List of Figures
FIGURE 1. COMPANION DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 2. COMPANION DIAGNOSTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. COMPANION DIAGNOSTICS MARKET DYNAMICS
FIGURE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. COMPANION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 22. COMPANION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. COMPANION DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 43. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 44. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 45. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 46. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 47. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 48. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 49. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 50. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 51. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 52. AMERICAS COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 53. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 54. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 55. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 56. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 57. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 58. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 59. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 60. ARGENTINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 61. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 62. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 63. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 64. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 65. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 66. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 67. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 68. BRAZIL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 69. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 70. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 71. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 72. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 73. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 74. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 75. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 76. CANADA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 77. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 78. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 79. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 80. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 81. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 82. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 83. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 84. MEXICO COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 85. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 86. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 87. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 88. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 89. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 90. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 91. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 92. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 93. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 94. UNITED STATES COMPANION DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 96. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 98. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 100. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 102. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 103. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 104. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 105. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 106. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 107. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 108. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 109. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 110. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 111. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 112. AUSTRALIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 113. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 114. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 115. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 116. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 117. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 118. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 119. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 120. CHINA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 121. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 122. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 123. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 124. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 125. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 126. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 127. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 128. INDIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 129. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 130. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 131. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 132. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 133. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 134. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 135. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 136. INDONESIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 137. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 138. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 139. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 140. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 141. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 142. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 143. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 144. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 145. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 146. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 147. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 148. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 149. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 150. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 151. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 152. MALAYSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 153. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 154. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 155. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 156. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 157. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 158. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 159. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 160. PHILIPPINES COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 161. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 162. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 163. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 164. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 165. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 166. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 167. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 168. SINGAPORE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 169. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 170. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 171. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 172. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 173. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 174. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 175. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 176. SOUTH KOREA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 177. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 178. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 179. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 180. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 181. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 182. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 183. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 184. TAIWAN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 185. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 186. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 187. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 188. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 189. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 190. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 191. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 192. THAILAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 193. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 194. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 195. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 196. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 197. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 198. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 199. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 200. VIETNAM COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 211. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 212. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 213. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 214. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 215. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 216. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 217. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 218. DENMARK COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 219. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 220. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 221. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 222. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 223. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 224. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 225. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 226. EGYPT COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 227. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 228. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 229. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 230. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 231. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 232. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 233. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 234. FINLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 235. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 236. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 237. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 238. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 239. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 240. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 241. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 242. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 243. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 244. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 245. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 246. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 247. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 248. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 249. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 250. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 251. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 252. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 253. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 254. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 255. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 256. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 257. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 258. ISRAEL COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 259. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 260. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 261. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 262. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 263. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 264. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 265. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 266. ITALY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 267. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 268. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 269. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 270. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 271. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 272. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 273. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 274. NETHERLANDS COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 275. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 276. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 277. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 278. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 279. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 280. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 281. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 282. NIGERIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 283. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 284. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 285. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 286. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 287. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 288. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 289. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 290. NORWAY COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 291. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 292. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 293. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 294. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 295. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 296. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 297. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 298. POLAND COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 299. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 300. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 301. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 302. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 303. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 304. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 305. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 306. QATAR COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 307. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 308. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 309. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 310. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 311. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 312. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 313. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 314. RUSSIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 315. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 316. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 317. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 318. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 319. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 320. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 321. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 322. SAUDI ARABIA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 324. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 325. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 326. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 327. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 328. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 329. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 330. SOUTH AFRICA COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 331. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 332. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 333. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 334. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 335. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 336. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 337. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 338. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 339. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 340. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 341. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 342. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 343. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2018-2023 (USD MILLION)
TABLE 344. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY CANCER, 2024-2030 (USD MILLION)
TABLE 345. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 346. SWEDEN COMPANION DIAGNOSTICS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 347. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 348. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 349. SWITZERLAND COMPANION DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 350. SWITZERLAND COMPANION DIAGNOSTICS MA

Companies Mentioned

  • Abbott Laboratories
  • Abnova Corporation
  • Agendia, Inc.
  • Agilent Technologies, Inc.
  • Almac Group
  • Amoy Diagnostics Co., Ltd.
  • ARUP Laboratories
  • Bio-Techne Corporation
  • Biogenex Laboratories, Inc
  • bioMérieux SA
  • Danaher Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Guardant Health, Inc
  • ICON PLC
  • Illumina, Inc.
  • Invivoscribe Technologies, Inc.
  • Myriad Genetics, Inc.
  • NG biotech
  • QIAGEN N.V.
  • R-Biopharm AG
  • Siemens AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages194
PublishedMay 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 7.3 Billion
Forecasted Market Value ( USD ) by 2030 $ 13.49 Billion
Compound Annual Growth Rate10.6%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Global Companion Diagnostics Market By Product (Assays, Kits, Reagents, System, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung, Colorectal Cancer, CVD, Infectious, Neurology), Sample Type (Tissue, Blood) & Region - Forecast to 2029 - Product Image

Global Companion Diagnostics Market By Product (Assays, Kits, Reagents, System, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung, Colorectal Cancer, CVD, Infectious, Neurology), Sample Type (Tissue, Blood) & Region - Forecast to 2029

  • Report
  • 349 Pages
  • Global
From
Companion Diagnostic Markets - the Future of Diagnostics by Application, Technology and Funding With Executive and Consultant Guides 2023-2027 - Product Image

Companion Diagnostic Markets - the Future of Diagnostics by Application, Technology and Funding With Executive and Consultant Guides 2023-2027

  • Report
  • 546 Pages
  • Global
From
Global Companion Diagnostics Market 2023-2027 - Product Image

Global Companion Diagnostics Market 2023-2027

  • Report
  • 168 Pages
  • Global
From
Companion Diagnostics Global Market Report 2024 - Product Image

Companion Diagnostics Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Companion Diagnostic Markets - The Future of Diagnostics by Application, Technology and Funding with Customized Forecasting/Analysis, and Executive and Consultant Guides - Product Image

Companion Diagnostic Markets - The Future of Diagnostics by Application, Technology and Funding with Customized Forecasting/Analysis, and Executive and Consultant Guides

  • Report
  • 541 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.